Departments of Cardiology, Rijnstate Hospital Arnhem and Radboud University Nijmegen Medical Centre, the Netherlands.
Neth Heart J. 2009 Aug;17(7-8):288-91. doi: 10.1007/BF03086268.
A 61-year-old male with a history of metastatic colorectal cancer was referred to our hospital for primary coronary intervention because of acute ST-elevation myocardial infarction. Coronary angiography, however, revealed no significant stenoses. When asked, the patient revealed that capecitabine (Xeloda(R)) was started by his oncologist one day before admission. It is known that this oral 5-FU analogue drug, used in metastatic colorectal cancer, can cause coronary artery spasms. The main treatment of capecitabine-induced vasospasm is discontinuation of the drug. Indeed, after cessation of the drug the patient remained free of symptoms and the ECG abnormalities normalised. (Neth Heart J 2009;17:288-91.).
一位 61 岁男性，患有转移性结直肠癌病史，因急性 ST 段抬高型心肌梗死被转至我院进行主要的冠状动脉介入治疗。然而，冠状动脉造影显示没有明显狭窄。当被问及这个问题时，患者透露他的肿瘤医生在入院前一天开始给他服用卡培他滨（希罗达®）。众所周知，这种用于转移性结直肠癌的口服 5-FU 类似物药物可引起冠状动脉痉挛。卡培他滨引起的血管痉挛的主要治疗方法是停止使用该药。事实上，停药后患者症状消失，心电图异常恢复正常。（Neth Heart J 2009;17:288-91.）。
